P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis

Naama Levy-Cooperman; Amit Reches; Denise Milovan; Noga Pinchuk; Guy Ben Bashat; Revital Shani-Hershkovitch; Amir Geva; Leon Y Deouell; Myroslava K Romach; Edward M Sellers

doi:10.1016/j.jalz.2010.05.1443

P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis

Naama Levy-Cooperman
, Amit Reches
, Denise Milovan
, Noga Pinchuk
, Guy Ben Bashat
, Revital Shani-Hershkovitch
, Amir Geva
, Leon Y Deouell
, Myroslava K Romach
, Edward M Sellers

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

Scopolamine acts as a muscarinic acetylcholine antagonist at M1 receptors. Evidence showing correlations between Alzheimer's disease (AD) and cholinergic deficits has lead to investigation of scopolamine as a cognitive deficit model. Previously, a dose of 0.4mg scopolamine induced cognitive deficits on tasks of divided attention (DA), vigilance, and short-term memory (STM) in healthy volunteers (Milovan, 2008). The goal of this study was to evaluate scopolamine-induced deficits on measures of electrophysiological activity (P50, P3a/P3b), analyzed using a novel brain network analysis technique (ElMindA), and cognitive tasks of vigilance, DA, STM, and psychomotor skill administered using a computerized cognitive test battery

Original language	English
Pages (from-to)	S431-S432
Journal	Alzheimer's and Dementia
Volume	6
DOIs	https://doi.org/10.1016/j.jalz.2010.05.1443
State	Published - Jun 2010

Access to Document

10.1016/j.jalz.2010.05.1443

Cite this

Levy-Cooperman, N., Reches, A., Milovan, D., Pinchuk, N., Ben Bashat, G., Shani-Hershkovitch, R., Geva, A., Deouell, L. Y., Romach, M. K., & Sellers, E. M. (2010). P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis. Alzheimer's and Dementia, 6, S431-S432. https://doi.org/10.1016/j.jalz.2010.05.1443

@article{a4340af2d50541baa8c2a94457f56b93,

title = "P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis",

abstract = "Scopolamine acts as a muscarinic acetylcholine antagonist at M1 receptors. Evidence showing correlations between Alzheimer's disease (AD) and cholinergic deficits has lead to investigation of scopolamine as a cognitive deficit model. Previously, a dose of 0.4mg scopolamine induced cognitive deficits on tasks of divided attention (DA), vigilance, and short-term memory (STM) in healthy volunteers (Milovan, 2008). The goal of this study was to evaluate scopolamine-induced deficits on measures of electrophysiological activity (P50, P3a/P3b), analyzed using a novel brain network analysis technique (ElMindA), and cognitive tasks of vigilance, DA, STM, and psychomotor skill administered using a computerized cognitive test battery",

author = "Naama Levy-Cooperman and Amit Reches and Denise Milovan and Noga Pinchuk and \{Ben Bashat\}, Guy and Revital Shani-Hershkovitch and Amir Geva and Deouell, \{Leon Y\} and Romach, \{Myroslava K\} and Sellers, \{Edward M\}",

year = "2010",

month = jun,

doi = "10.1016/j.jalz.2010.05.1443",

language = "English",

volume = "6",

pages = "S431--S432",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc.",

}

Levy-Cooperman, N, Reches, A, Milovan, D, Pinchuk, N, Ben Bashat, G, Shani-Hershkovitch, R, Geva, A, Deouell, LY, Romach, MK & Sellers, EM 2010, 'P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis', Alzheimer's and Dementia, vol. 6, pp. S431-S432. https://doi.org/10.1016/j.jalz.2010.05.1443

TY - JOUR

T1 - P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis

AU - Levy-Cooperman, Naama

AU - Reches, Amit

AU - Milovan, Denise

AU - Pinchuk, Noga

AU - Ben Bashat, Guy

AU - Shani-Hershkovitch, Revital

AU - Geva, Amir

AU - Deouell, Leon Y

AU - Romach, Myroslava K

AU - Sellers, Edward M

PY - 2010/6

Y1 - 2010/6

N2 - Scopolamine acts as a muscarinic acetylcholine antagonist at M1 receptors. Evidence showing correlations between Alzheimer's disease (AD) and cholinergic deficits has lead to investigation of scopolamine as a cognitive deficit model. Previously, a dose of 0.4mg scopolamine induced cognitive deficits on tasks of divided attention (DA), vigilance, and short-term memory (STM) in healthy volunteers (Milovan, 2008). The goal of this study was to evaluate scopolamine-induced deficits on measures of electrophysiological activity (P50, P3a/P3b), analyzed using a novel brain network analysis technique (ElMindA), and cognitive tasks of vigilance, DA, STM, and psychomotor skill administered using a computerized cognitive test battery

AB - Scopolamine acts as a muscarinic acetylcholine antagonist at M1 receptors. Evidence showing correlations between Alzheimer's disease (AD) and cholinergic deficits has lead to investigation of scopolamine as a cognitive deficit model. Previously, a dose of 0.4mg scopolamine induced cognitive deficits on tasks of divided attention (DA), vigilance, and short-term memory (STM) in healthy volunteers (Milovan, 2008). The goal of this study was to evaluate scopolamine-induced deficits on measures of electrophysiological activity (P50, P3a/P3b), analyzed using a novel brain network analysis technique (ElMindA), and cognitive tasks of vigilance, DA, STM, and psychomotor skill administered using a computerized cognitive test battery

U2 - 10.1016/j.jalz.2010.05.1443

DO - 10.1016/j.jalz.2010.05.1443

M3 - Meeting Abstract

SN - 1552-5260

VL - 6

SP - S431-S432

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

ER -

P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis

Abstract

Access to Document

Fingerprint

Cite this